All In Biotech

Drug Trial Radar · NCT04879043

Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma

A Phase 1/2a, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HDP-101 in Patients With Plasma Cell Disorders Including Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

78

Planned (sponsor's estimate)

Start

Feb 7, 2022

Primary completion

Mar 2028

Study completion Sep 2028

Sponsor

Lead sponsor
Heidelberg Pharma AGIndustry
Sponsor type
Industry
First posted
May 10, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess the safety, tolerability, pharmacokinetics (PK) and the therapeutic potential of HDP-101 in patients with plasma cell disorders including multiple myeloma.

Conditions

  • Multiple Myeloma
  • Plasma Cell Disorder

Interventions

  • HDP-101Drug

    HDP-101 is available as lyophilized white powder for preparation of infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of patients who experience dose-limiting toxicity (DLT) during the first cycle of treatment - Part 1 as defined in Clinical Study ProtocolTime frame: Up to Day 21 (from first dose)
  2. Objective response rate (ORR)Time frame: Through study completion, an average of 1 year

Locations

24 sites in 5 countries. Site status is shown where the registry gives one.

  • Winship Cancer Institute of Emory University

    Atlanta, Georgia · Recruiting

  • Norton Healthcare, Inc.

    Louisville, Kentucky · Not yet recruiting

  • Nebraska Cancer Institute

    Omaha, Nebraska · Recruiting

  • Mount Sinai, The Tisch Cancer Instutute

    New York, New York · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Charité - Campus Benjamin Franklin Med. Klinik m.S. Hämatologie, Onkologie

    Berlin, Germany · Withdrawn

  • Klinikum Chemnitz gGmbH, Klinik f. Innere Medizin III

    Chemnitz, Germany · Withdrawn

  • Universitätsklinikum Köln

    Cologne, Germany · Withdrawn

  • Asklepios Klinik Altona, Haematologie und internistische Onkologie

    Hamburg, Germany · Withdrawn

  • Universitätsklinikum Heidelberg

    Heidelberg, Germany · Active not recruiting

  • Universitätsklinikum Schleswig-Holstein

    Kiel, Germany · Withdrawn

  • UKSH Campus Lübeck Klinik für Hämatologie und Onkologie

    Lübeck, Germany · Active not recruiting

  • Universitätsklinikum Mainz

    Mainz, Germany · Withdrawn

  • Semmelweis University, Belgyogyaszati es Onkologiai Klinika

    Budapest, Hungary · Recruiting

  • National Institute of Oncology, Department of Oncological Internal Medicine

    Budapest, Hungary · Withdrawn

  • Pécsi Tudományegyetem Klinikai Központ

    Pécs, Hungary · Not yet recruiting

  • Pratia Onkologia Katowice

    Katowice, Poland · Recruiting

  • Pratia Onkologia Kraków

    Krakow, Poland · Recruiting

  • Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi

    Lodz, Poland · Withdrawn

  • Szpital Wojewodzki w Opolu

    Opole, Poland · Withdrawn

  • AIDPORT Sp. zo.o.

    Skórzewo, Poland · Recruiting

  • MICS Centrum Medyczne Torun

    Torun, Poland · Recruiting

  • Arensia Clinics SRL

    Bucharest, Romania · Recruiting

  • Oncology Institute Prof. Dr. Ion Chiricuta I.O.C.N.

    Cluj-Napoca, Romania · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.